We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024 PARIS, FRANCE, 24 avril 2024 - Ipsen (Euronext : IPN ;...
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext:...
Ipsen et Skyhawk Therapeutics annoncent la signature d'un accord de collaboration de recherche visant le ciblage d’ARN dans les maladies neurologiques rares Ipsen conclut un accord...
Ipsen publie son Document d’enregistrement universel 2023 Ipsen publie sonDocument d’enregistrement universel 2023 PARIS, FRANCE, 17 avril 2024 - Ipsen (Euronext : IPN ; ADR : IPSEY...
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares...
Ipsen et Sutro Biopharma annoncent la signature d'un accord exclusif de licence mondiale pour un conjugué anticorps-petite molecule ciblant les tumeurs solides Ipsen obtient les droits...
Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical developmentSTRO-003 targets ROR1, a...
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle relative au nombre total des droits de voteet...
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares...
Ipsen S.A. publie ses comptes consolidés 2023 Ipsen S.A. - Etats financiers consolidés 2023 Pièce jointe Ipsen - Comptes consolidés 2023
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 6.9 | 6.50329877474 | 106.1 | 115.9 | 105.3 | 85595 | 111.64269675 | DE |
4 | 3.3 | 3.00820419325 | 109.7 | 115.9 | 104.6 | 64447 | 109.30921058 | DE |
12 | 7 | 6.60377358491 | 106 | 115.9 | 99.7 | 76880 | 106.31248967 | DE |
26 | -4.3 | -3.66581415175 | 117.3 | 118 | 99.7 | 76393 | 106.08866531 | DE |
52 | 5.8 | 5.41044776119 | 107.2 | 130.7 | 99.7 | 72317 | 110.59983123 | DE |
156 | 32.88 | 41.0384423365 | 80.12 | 130.7 | 77 | 87576 | 99.0116327 | DE |
260 | -2.1 | -1.8245004344 | 115.1 | 130.7 | 34.2 | 110474 | 88.83357897 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions